Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Harold Schnitzer Diabetes Health Center, 3181 Southwest Sam Jackson Park Road, L607, Portland, OR 97239-3098, USA.
Department of Biomedical Engineering, Oregon Health & Science University, Mail Code: CH13B, 3303 Southwest Bond Avenue, Portland, OR 97239, USA.
Endocrinol Metab Clin North Am. 2020 Mar;49(1):179-202. doi: 10.1016/j.ecl.2019.10.008. Epub 2019 Dec 10.
Treatment of type 1 diabetes with exogenous insulin often results in unpredictable daily glucose variability and hypoglycemia, which can be dangerous. Automated insulin delivery systems can improve glucose control while reducing burden for people with diabetes. One approach to improve treatment outcomes is to incorporate the counter-regulatory hormone glucagon into the automated delivery system to help prevent the hypoglycemia that can be induced by the slow pharmacodynamics of insulin action. This article explores the advantages and disadvantages of incorporating glucagon into dual-hormone automated hormone delivery systems.
用外源性胰岛素治疗 1 型糖尿病常常导致日常血糖变化不可预测和低血糖，这可能很危险。自动化胰岛素输送系统可以改善血糖控制，同时减轻糖尿病患者的负担。一种改善治疗效果的方法是将抗胰岛素激素胰高血糖素纳入自动化输送系统，以帮助预防胰岛素作用缓慢引起的低血糖。本文探讨了将胰高血糖素纳入双激素自动化激素输送系统的优缺点。
